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Abstract
The discovery that drugs targeting a single G protein-coupled receptor (GPCR) can differentially modulate distinct subsets of
the receptor signaling repertoire has created a challenge for drug discovery at these important therapeutic targets. Here, we
demonstrate that a single label-free assay based on cellular impedance provides a real-time integration of multiple signaling
events engaged upon GPCR activation. Stimulation of the b2-adrenergic receptor (b2AR) in living cells with the prototypical
agonist isoproterenol generated a complex, multi-featured impedance response over time. Selective pharmacological
inhibition of specific arms of the b2AR signaling network revealed the differential contribution of Gs-, Gi- and Gbc-
dependent signaling events, including activation of the canonical cAMP and ERK1/2 pathways, to specific components of
the impedance response. Further dissection revealed the essential role of intracellular Ca
2+ in the impedance response and
led to the discovery of a novel b2AR-promoted Ca
2+ mobilization event. Recognizing that impedance responses provide an
integrative assessment of ligand activity, we screened a collection of b-adrenergic ligands to determine if differences in the
signaling repertoire engaged by compounds would lead to distinct impedance signatures. An unsupervised clustering
analysis of the impedance responses revealed the existence of 5 distinct compound classes, revealing a richer signaling
texture than previously recognized for this receptor. Taken together, these data indicate that the pluridimensionality of
GPCR signaling can be captured using integrative approaches to provide a comprehensive readout of drug activity.
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Introduction
G protein-coupled receptors (GPCRs) are the most abundant
class of cell surface receptors, responding to various types of
endogenous stimuli, including hormones, neurotransmitters and
odorants, and are the largest family of therapeutic targets [1,2].
Through interactions with various G protein [3] and non-G protein
effectors [4], GPCRs elicit a diverse array of signaling events,
including production of second messengers, activation of phosphor-
ylation cascades, modulation of ion channel activity and transcrip-
tional regulation. Although it was originally assumed that a given
GPCR controlled the activity of a single signaling pathway, it is now
recognized that individual receptors can elicit multiple signaling
events resulting in global changes in cellular physiology, thus
highlighting the pluridimensionality of GPCR signaling [5].
Furthermore, certain GPCR ligands have been shown to differen-
tially modulate distinct subsets of this signaling repertoire, a
phenomenon referred to as ‘‘ligand-biased signaling’’ or ‘‘functional
selectivity’’ [5–7]. A recent review of the published literature
indicates that ligand-biased signaling occurs for a large number of
GPCRs involved in a diverse array of physiological functions [8].
For example, several peptide ligands for the angiotensin AT1A
receptor show a clear preference in the activation of b-arrestin-
dependent signaling events, yet possess no intrinsic efficacy towards
G protein-dependent signaling [9,10]. Even more striking is the
inversion of efficacy observed for some b-adrenergic receptor
ligands, which act as inverse agonists for cAMP production yet
behave as agonists for the activation of the ERK1/2 MAPK
pathways [11,12]. Harnessing such ligand functional selectivity
could represent a promising avenue in drug development, as the
design of compounds that selectively modulate a pathway involved
in a given pathology without collateral effects on other pathways
could provide therapeutic benefit with a decreased risk of side
effects. Indeed, several recent studies have suggested that function-
allyselective ligands mayprovide clinicallyrelevant advantages over
unbiased ligands at the same receptor [13–15].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29420Yet, detecting the full extent of such ligand ‘‘functional
selectivity’’ remains a non-trivial technical challenge and has
traditionally involved measuring the relative efficacy of ligands
towards distinct pathways engaged by a given receptor using
multiple assays. One considerable challenge in obtaining a full
description of ligand activity at a given GPCR is the lack of
knowledge about the complete signaling repertoire of most
receptors. In addition, monitoring multiple signaling pathways
can be time and resource consuming and involves the use of
different assay formats with different sensitivity and dynamic
ranges that can lead to spurious conclusions.
An integrative approach that could capture the global signaling
profile of a ligand in a single assay would therefore greatly facilitate
the identification of biased ligands and enable their classification
into pharmacologically relevant categories. Besides the potential
impact on the drug discovery process, such an approach could also
provide greater insight into how the pluridimensionality of GPCR
signaling is integrated into an overall cellular response. A string of
recent studies has explored the use of such integrative assays to
study GPCR pharmacology using label-free, cell-based technolo-
gies developed to monitor real-time changes in higher-order
cellular events such as morphology, viability, adhesion and mass
distribution [16–20]. Thus far, however, little effort has been made
to understand how the pluridimensionality of GPCR signaling is
recapitulated in the responses generated by these assays. One
recently developed label-free assay is the measurement of cellular
impedance. The use of impedance measurements to monitor
global cellular activity is based on the principle that the adhesion
of cells directly onto microelectrodes induces changes in the local
ionic environment at the electrode/solution interface, conferring
an increase in electrode impedance (see Materials and Methods).
Any changes in cell morphology and/or adhesion that modulate
the physical contact between cell and electrode will be reflected by
changes in impedance. Recently, impedance measurements have
been used to monitor GPCR signaling [16,18,19] and to assess
general mechanisms of drug action [21].
In the present study, we sought to determine if impedance
signatures represent an integrative measure of the receptor
signaling repertoire that can be used to differentiate among
ligands with distinct signaling profiles. Using the b2-adrenergic
receptor (b2AR) as a model, we dissected the impedance responses
from individual ligand-receptor pairs and associated the activation
of specific signaling events with distinct features of the impedance
curves. This dissection of the impedance responses led to the
identification of a novel b2AR-mediated Ca
2+ signaling event,
highlighting the strength of such an integrative readout of cellular
response to reveal biological processes even at a well-characterized
target. Finally, we performed an unsupervised clustering analysis
that permitted a rapid and systematic classification of compounds
based on the impedance signatures obtained in both heterologous
and primary cell cultures, demonstrating that impedance respons-
es represent signatures that are predictive of the global signaling
profiles of b-adrenergic ligands previously shown to display
functional selectivity [10,11].
Results
b2AR activation elicits a multi-featured, time-resolved
impedance response
We first sought to determine if impedance measurements could
provide a composite representation of the multiple signaling events
elicited upon receptor activation. To assess this possibility,
impedance measurements were made in HEK293S cells stably
overexpressing the human b2AR (6HisHA-b2AR-HEK293S)
following treatment with the prototypical b2AR-selective agonist
isoproterenol (ISO). As shown in Figure 1A, stimulation of cells
with ISO led to a concentration-dependent, time-resolved and
feature-rich impedance response. Immediately following ISO-
stimulation, the impedance response briefly decreases below zero
before quickly reverting to a positive slope, producing what is
referred to hereafter as the ‘‘transient negative phase’’ (Figure 1B).
Subsequently, the impedance rises sharply at first (‘‘rapid ascending
phase’’), followed by a later ‘‘slow ascending phase’’ before reaching
a maximum, after which it decays slowly. This response was found
to be b2AR-specific since the response was blocked by the selective
b2AR antagonist ICI118,551 (ICI) but was not affected by the
b1AR-selective antagonist CGP20712A (Figure S1A). In addition,
the concentration-response curve describing the maximum imped-
ance response elicited by ISO was progressively right-shifted with
increasing concentrations of ICI, indicating a competitive antago-
nism of the response by b2AR blockade (Figure S1B). Further
supporting the b2AR specificity of the response, we observed a
qualitatively similar ICI-sensitive impedance response in the
parental HEK293S cell line, which endogenously express low
amounts of b2AR (Figure S2). Although the impedance response
maintains the same general shape, a decrease in the magnitude of
the positive component of the impedance response and a larger
transient negative phase was observed.
Further analyses of the impedance responses were performed in
the 6HisHA-b2AR-HEK293S cell line to obtain a more robust
response to receptor stimulation. The distinct features of the
response (i.e. depth and duration of the transient negative phase,
slope of the rapid ascending phase and the maximal impedance
response) were differentially modulated by increasing concentra-
tions of ISO, suggesting the contribution of distinct signaling events
to discrete components of the impedance response. For instance,
concentration-response curves describing either the maximum
impedance response (Figure 1C) or the slope of the rapid
ascending phase (Figure 1D), revealed EC50 values that differ by
more than an order of magnitude. Furthermore, two concentration-
dependent components can also be distinguished in the transient
negative phase. At low concentrations (i.e. under 1 mM), ISO
promoted a concentration-dependent increase in the magnitude of
the minimum (Figure 1A). At higher concentrations, however, no
further increase in depth was observed, but a quicker recovery from
negative impedance values and a shift of the minimum to earlier
time points occurred, thus reducing the duration of the transient
negative phase. Receptor expression was also found to differentially
influence distinct components of the impedance response. As
illustrated above, overexpression of the b2AR selectively increases
the positive components of the impedance response while
decreasing the duration and amplitude of the transient negative
phase (Figure S2A). These results further support the above data
that the signaling events contributimg to the transient negative
phase are fully activated with fewer stimulated receptors. As the
stimulus strength (i.e. agonist concentration) or receptor number is
increased, the impedance response becomes more positive, likely
due to the engagement of another signaling event with a weaker
stimulus-coupling. Altogether, these results suggest that the
impedance response obtained reflects the integration of multiple
signaling events which may be individually represented in the
various components of the response.
Impedance responses encode multiple signaling events
upon b2AR activation
b2AR activation is known to elicit at least two distinct signaling
events in HEK293S cells: cAMP accumulation via adenylyl
cyclase (AC) stimulation and activation of the ERK1/2 MAPK
b2AR Signaling Integration and Ligand Signatures
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29420Figure 1. Ligand-induced changes in impedance are multi-featured and concentration-dependent. (A) Impedance measurements were
obtained in 6HisHA-b2AR-HEK293S cells following treatment with isoproterenol (ISO) at the concentrations indicated. Impedance responses
(represented as changes in Cell Index) were normalized and baseline-corrected as described in Materials and Methods and Figure S9. Inset:
Enlargement of the transient negative phase of the response. (B) Features of the ISO impedance signature with the inset showing an enlargement of
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are represented in the impedance response, 6HisHA-b2AR-
HEK293S cells were pre-treated, prior to ISO stimulation, with
the AC inhibitor SQ22536 to inhibit cAMP production or the
MEK inhibitor U0126 to block ERK1/2 activation. Interest-
ingly, both of these inhibitors led to similar decreases in the slope
of the slow ascending phase and the maximum impedance
response without affecting the transient negative phase or the
rapid ascending phase (Figure 2A,B). A similar effect on the
impedance response was observed using the K97A dominant
negative mutant of MEK1 (Figure S3). SQ22536 and U0126
w e r ef o u n dt ob ep a t h w a y - s p e c i f i cs i n c et h e yb l o c k e dt h eI S O -
stimulated accumulation of cAMP and activation of ERK1/2,
respectively, and had no significant effects on the other signaling
pathway (Figure 2C,D). The observation that cAMP and
ERK1/2 pathway inhibition led to similar changes in the
impedance response suggested that these pathways may
converge on a common mechanism underlying the observed
changes in impedance. Consistent with this notion, concurrent
inhibition of both pathways did not lead to a greater attenuation
of the maximal ISO-stimulated impedance response than
inhibition of either the cAMP or ERK1/2 pathway alone
(Figure 2E).
From the above data, it is clear that cAMP production and
MAPK activation are not sufficient to explain the entire ISO
impedance response since a considerable residual signal is
observed when both of these pathways are inhibited. To further
explore the source of this residual response, we examined the role
of the G proteins themselves. The b2AR is known to couple to
both Gs and Gi [22]. Chronic treatment with cholera toxin (CTX),
which selectively downregulates Gs [23], led to a severe
attenuation of the impedance response, including a complete loss
of the transient negative phase and a significant reduction of the
maximum response (Figure 3A). Interestingly, CTX inhibited
ISO-induced cAMP accumulation to a similar extent as the AC
inhibitor SQ22536, with no effect on ERK1/2 activation
(Figure 3B,C), yet the effect of CTX on the impedance response
is clearly distinct from the one observed following inhibition of the
cAMP pathway (Figure S4A), suggesting the contribution of
additional Gs-dependent signaling events other than cAMP
accumulation to the impedance response. Selective inhibition of
Gi-dependent signaling with pertussis toxin (PTX) led to changes
Figure 2. Contribution of cAMP accumulation and ERK1/2 activation to the ISO-promoted impedance response. (A,B) Pre-treatment
for 1 hour with the adenylyl cyclase inhibitor, SQ2236 (100 mM, A), or the MEK inhibitor, U0126. (5 mM, B) leads to decreases in the kinetics of the slow
ascending phase and the maximum value of ISO-promoted impedance response. (C,D) SQ22536 and U0126 selectively inhibit ISO-promoted cAMP
accumulation (C) and ERK1/2 activation (D), respectively. (E) Concurrent inhibition of cAMP and ERK1/2 pathways with SQ22536 and U0126 does not
lead a further attenuation of the ISO-promoted maximum impedance response than either inhibitor alone. Data represent means of at least three
independent experiments (6 SEM for C–E). For statistical analysis, individual conditions were compared in C and D using a one-way ANOVA and a
Bonferroni post-hoc test. *** P,0.001.
doi:10.1371/journal.pone.0029420.g002
the first 10 minutes post-stimulation. (C,D) Concentration-response curves describing the maximum impedance response generated (C) and the
slope of the rapid ascending phase (D) reveal distinct EC50 values. Data represent means of at least three independent experiments (6 SEM for C and
D). For clarity, error bars are not shown for impedance responses. Typical experimental variability in the impedance responses is demonstrated in
Figure S5.
doi:10.1371/journal.pone.0029420.g001
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by CTX (Fig. 3A). Specifically, a transient negative phase was still
observed following PTX treatment, although it was reduced and
delayed compared to vehicle treatment. Although both treatments
led to significant reductions in the maximum impedance response,
the influence of PTX on this phase of the curve was not as severe
as CTX. Taken together, these results indicate that Gs and Gi
signaling have distinguishable contributions to the overall
impedance response. PTX treatment significantly inhibited
ERK1/2 activation but did not affect cAMP production
(Figure 3B,C). However, the contribution of Gi cannot be solely
attributed to ERK1/2 activation since complete abolition of this
pathway by U0126 (Fig. 2D) affected the ISO-stimulated
impedance response to a lesser extent than PTX (Figure S4B),
which only partially blocked ERK1/2 activation. Although the
differences observed between acute pharmacological inhibition of
cAMP production and ERK1/2 activation versus chronic
inhibition of Gs and Gi suggest the contribution of alternative G
protein-dependent signaling pathways to the impedance response,
we cannot exclude the possibility that the chronic treatment with
CTX and PTX may affect other downstream components
involved in the response.
Next, we assessed the contribution of Gbc subunits to the
impedance response using the pharmacological inhibitor, gallein,
which selectively inhibits interactions between Gbc and effector
molecules [24]. Pre-treatment with gallein inhibited ERK1/2
activation, with no effect on cAMP accumulation (Figure 3B,C),
and led to an impedance response with reduced kinetics of the
slower ascending phase and a decreased maximum response
(Figure 3D), The effect of gallein was similar overall to that
observed upon inhibition of the ERK1/2 pathway; however, Gbc
inhibition led to an additional loss of the slow decay phase (Figure
S4C) indicating the existence of additional Gbc-dependent
signaling beyond ERK1/2.
Altogether, these data demonstrate that a variety of G protein-
dependent signaling events are integrated in the ISO-stimulated
impedance response, including the activation of canonical second
messenger pathways (i.e. cAMP and ERK1/2) and additional G
protein-dependent events not yet identified.
Clustering analysis of impedance signatures reveals
compound classes with distinct signaling profiles
After demonstrating that impedance responses represent the
integration of multiple signaling events elicited upon receptor
activation, we hypothesized that compounds with different
signaling profiles at the b2AR would generate distinct impedance
signatures. Impedance responses were obtained for a series of b-
adrenergic ligands (Figures 4A–I and S5) at concentrations
providing .99% receptor occupancy based on their reported Kd
values [25–27]. Differences among ligand signatures were
determined by comparing the area between individual impedance
curves. Visualization of the pairwise differences using a visual
assessment of clustering tendency (VAT; see Materials and Methods)
suggested that the ligands fall into 5 distinct clusters (Figure S6),
which we confirmed by complete linkage hierarchical clustering
[28] (Figure 4J). With the exception of Group V compounds,
Figure 3. Contribution of GS,G i, and Gb/c to the ISO-promoted impedance response. (A) Inhibition of GS- and Gi-dependent signaling by
16 hour treatment with cholera toxin (CTX, 200 ng/ml) and pertussis toxin (PTX, 100 ng/ml), respectively, leads to distinct changes in the ISO-
promoted impedance response. Inset: Enlargement of the transient negative phase of the response. (B,C) Effects of CTX, PTX or gallein (Gall, 100 mM,
1 hour pre-treatment) on ISO-promoted cAMP (B) and ERK1/2 responses (C). (D) Inhibition of Gbc-dependent signaling by Gall leads to decreases in
the kinetics of the slow ascending phase and maximum value of ISO-promoted impedance response. Data represent means of at least three
independent experiments (6 SEM for B and C). For statistical analysis, individual conditions were compared in B and C using a one-way ANOVA and a
Bonferroni post-hoc test. *** P,0.001, ** P,0.01, and * P,0.05.
doi:10.1371/journal.pone.0029420.g003
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29420Figure 4. Impedance signatures reveal 5 distinct compound classes among b-adrenergic ligands. (A–E) Impedance responses were
obtained following stimulation with saturating concentrations of the following ligands: ISO (50 mM), epinephrine (EPI, 75 mM), salbutamol (SALB,
100 mM), salmeterol (SALM, 1 mM), alprenolol (ALP, 1 mM), bucindolol (BUC, 1 mM), labetalol (LAB, 1 mM), pindolol (PIN, 1 mM), propranolol (PRO,
1 mM), carvedilol (CARV, 1 mM), metoprolol (MET, 20 mM), timolol (TIM, 1 mM), ICI118,551 (ICI, 1 mM) and atenolol (ATEN, 100 mM). Impedance
responses, as represented by the Cell Index, were normalized and baseline-corrected. The first 10 minutes of the impedance responses are enlarged
b2AR Signaling Integration and Ligand Signatures
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differences between compound classes reflect differences in the
specific features defined in our previous analysis of the ISO-
promoted impedance response. We see great variation, for
example, in the maximum impedance responses generated
between compound classes. We also observed clear distinctions
between groups in the transient negative phase of the response;
Group I compounds elicit a relatively short-lived transient negative
phase while Group IV compounds completely lack this feature
(Figure 4F–I).
To determine the relationship between ligand signaling profiles
with the compound classes obtained in the above analysis of
impedance signatures, we assayed each of the ligands for their
ability to stimulate cAMP accumulation and ERK1/2 activation
in conditions identical to those used for the impedance
measurements (Figure 4K,L). Group I ligands, which include
ISO, have high agonist efficacies (full or strong partial agonists) for
both cAMP and ERK1/2 responses. Group II ligands are only
weak partial agonists toward the ERK1/2 pathway but elicit as
strong cAMP responses as Group I. Group III ligands are weak
partial agonists for both cAMP and ERK1/2 pathways. Group IV
ligands elicit very weak signaling responses for both pathways.
Group V ligands are inverse agonists towards both cAMP and
ERK1/2 responses. The compound classes defined by impedance
signatures are thus highly predictive of the relative efficacies of
ligands to elicit cAMP accumulation and ERK1/2 activation.
The role of intracellular Ca
2+ in the b2AR-mediated
impedance response
Since neither cAMP accumulation nor ERK1/2 activation
contribute to the transient negative phase observed for most ligand
impedance signatures, we reasoned that further analysis of this
feature could reveal additional texture among ligand signaling
profiles. The shape of the transient negative phase can be defined
by two parameters, the duration and minimum value of the
negative response. Although no significant correlation between
these two parameters could be observed when all of the ligands
were considered (r
2=0.06, p=0.79) (Figure 5), a strong linear
relationship emerged when considering Groups III and IV
compounds alone (r
2=0.97, p=9610
25), reflecting a fundamen-
tal difference in the nature of the transient negative phase between
Group I/II ligands and Group III/IV ligands. Indeed, Group I
and II ligands have a shorter-lived transient negative phase than
would be predicted given their amplitudes (Figure 5 inset),
suggesting that these compounds may selectively engage a
signaling pathway that accelerates the rapid ascending phase thus
shortening the duration of the transient negative phase. Given that
many GPCRs are capable of activating pathways leading to an
increase in intracellular [Ca
2+], we assessed whether a b2AR-
mediated Ca
2+ response could be responsible for accelerating this
phase. Consistent with this hypothesis, only Group I and II ligands
elicited a significant increase in intracellular [Ca
2+], with ISO and
epinephrine (Group I) eliciting a much stronger Ca
2+ response
than salbutamol and salmeterol (Group II) (Figure 6A). This
response was found to be b2AR-selective since receptor blockade
with the b2AR-selective antagonist ICI completely abolished the
ISO-stimulated increase in intracellular [Ca
2+]( Figure S7). This
b2AR-promoted increase in [Ca
2+] was sensitive to the inositol
trisphosphate (IP3) receptor antagonist, 2-aminoethoxydiphenyl
borate (2-APB) and the intracellular Ca
2+ chelator BAPTA-AM
(Figure 6B), implicating a mobilization from IP3-gated intracel-
lular stores in the calcium response. Pre-treatment with either 2-
APB or BAPTA-AM strongly inhibited the ascending phases of the
impedance response (Figure 6C), supporting the hypothesis that
Ca
2+ mobilization is a key event in the b2AR-mediated impedance
response.
Interestingly, pre-treatment of cells with either 2-APB or
BAPTA-AM significantly modulated the impedance responses
not only for ligands in Groups I and II, but also Groups III and
IV, which do not elicit a detectable increase in [Ca
2+]
(Figure 6A,C–F). Given that both 2-APB and BAPTA-AM not
only inhibit ligand-induced Ca
2+ mobilization, but also decrease
the basal intracellular [Ca
2+]( Figure 6G), we hypothesized that a
minimal concentration of intracellular Ca
2+ is required to initiate
the cellular events underlying the ascending phases of the
impedance response. To test this hypothesis, we pre-treated cells
with the sarco/endoplasmic reticulum Ca
2+ ATPase inhibitor
thapsigargin (TG), which will lead to an increase in intracellular
Ca
2+ by preventing the reuptake of Ca
2+, thus emptying the
intracellular stores. Since the intracellular Ca
2+ stores are already
empty, ISO does not elicit an additional Ca
2+ release following
TG inhibition (Figure S8A). Yet, in contrast with what was
observed with 2-APB and BAPTA-AM, and despite the absence of
Figure 5. Analysis of the transient negative phase of the
impedance response reveals differences between Group I and
II vs Group III and IV ligands. The duration of the negative phase
was plotted as a function of the minimum value for all ligands
promoting a transient negative response (Group I–IV). Compound
classes are indicated by color: Group I – blue, Group II – purple, Group III
– green, and Group IV – pink. Lines of best fit were determined using
weighted total least squares regression for all ligands (black dotted line,
r
2=0.06, P=0.79) and for Group III and IV compounds only (red dotted
line, r
2=0.97, P=9.0610
25). Inset: The comparison of transient negative
phases promoted by the prototypical Group I and Group III ligands EPI
(dark blue) and LAB (green), respectively. Data represent means of at
least three independent experiments (6 SEM).
doi:10.1371/journal.pone.0029420.g005
in panels F–I.( J) Ligands were categorized according to complete linkage hierarchical clustering (see Materials and Methods) determined by
comparing the area between individual curves. The dashed line represents the calculated threshold value defining compound dissimilarity. (K,L)
Efficacies of compounds for cAMP (K) and ERK1/2 (L) pathways performed in conditions identical to those used for impedance measurements in (A–
E). Data represent means of at least three independent experiments (6 SEM for K and L).
doi:10.1371/journal.pone.0029420.g004
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2+ in the impedance response to b2AR stimulation. (A) Peak Ca
2+ responses generated upon
stimulation with the indicated ligand (1 mM each). The intracellular Ca
2+ concentration is represented in relative luminescence units (RLU) emitted by
the obelin biosensor (see Materials and Methods). (B) Pre-treatment for 1 hour with the IP3 receptor antagonist 2-aminoethoxydiphenyl borate (2-
APB, 200 mM) or the intracellular Ca
2+ chelator BAPTA-AM (20 mM) completely abolishes the ISO-promoted Ca
2+ response. (C–F) Pre-treatment with 2-
APB or BAPTA-AM also leads to an inhibition of the rapid ascending phase and a decrease in the maximum impedance responses of ligands from
Groups I to IV: ISO (C), salbutamol (SALB, D), alprenolol (ALP, E) and propranolol (PRO, F), respectively (1 mM each). (G) Pre-treatment with 2-APB or
BAPTA-AM significantly decreases basal intracellular [Ca
2+]. Data represent means of at least three independent experiments (6 SEM for A, B and G).
For statistical analysis, individual conditions were compared in G using a one-way ANOVA and a Bonferroni post-hoc test. *** P,0.001 and * P,0.05.
doi:10.1371/journal.pone.0029420.g006
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2+ release, the TG treatment does not inhibit the rapid
ascending phase of the impedance response (Figure S8B). In fact,
it modestly potentiated the maximal response while slightly
reducing the slope of the slow ascending phase. Taken together,
these data support the notion that it is the intracellular [Ca
2+]
itself, more than the de novo Ca
2+ release, that is the prime
determinant of the ascending phases. The fundamental role of
Ca
2+ in the impedance response is further demonstrated by the
effect of the Ca
2+ ionophore A23187 on the impedance responses
(Figure 7). On its own, the ionophore elicits only a weak positive
impedance response. However, it greatly potentiates the imped-
ance responses obtained upon stimulation with either b-adrenergic
ligands or the direct activator of adenylyl cyclase, forskolin,
yielding responses with faster kinetics of the ascending phase and a
higher overall maximum response. This effect is particularly
evident when considering the forskolin-stimulated impedance
response, which consists of a long transient negative phase and a
slow rise to a relatively modest maximum response in the absence
of the Ca
2+ionophore. Taken together, these data explicitly
demonstrate the importance of Ca
2+ in the impedance response
and indicate that, under normal conditions, a minimal [Ca
2+]i s
needed to yield an increase in the b2AR-promoted impedance
response while additional Ca
2+ mobilization by Group I and II
ligands further accelerates the rapid ascending phase.
Figure 7. Increasing intracellular [Ca
2+] accelerates the rapid ascending phase and maximum impedance response. (A) Impedance
responses obtained following treatment with the Ca
2+ ionophore A23187 (1 mM), the adenylyl cyclase activator forskolin (10 mM) or the combined
stimulation with both. (B–E) Impedance responses obtained following stimulation with ISO (B), SALB (C), ALP (D) and PRO (E) (1 mM each) in the
presence or absence of A23187 (1 mM). Data represent means of at least three independent experiments.
doi:10.1371/journal.pone.0029420.g007
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vascular smooth muscle cells
To explore the applicability of impedance-based monitoring of
the signaling activity of a GPCR in its native cellular context, we
assessed the b2AR response in rat aortic vascular smooth muscle
cells (VSMCs). As was the case in b2AR-expressing HEK293S
cells, ISO induced a response that was completely abolished upon
pre-treatment with the b2AR-selective antagonist ICI (Figure 8A).
However, the shape of the impedance response was radically
different in VSMCs, indicating that cellular response to receptor
activation is cell type-specific. We next assessed the impedance
responses induced upon treatment with ligands representing each
of the 5 compound classes defined above (Figure 8B). Using the
same clustering criteria as in the 6HisHA-b2AR-HEK293S cells,
distinct impedance signatures for ISO (Group I), salbutamol
(Group II) and labetalol (Group III) were observed. Propranolol
(Group IV) and ICI (Group V) generated distinct signatures from
these other compounds, but could not be distinguished from each
other in VSMCs (Figure 8C), emphasizing the cell-type specificity
of the response. Altogether, these data indicate that despite the fact
that the magnitude and direction of the responses are cell-type
specific, quantitative analysis of impedance responses can be used
to detect distinct ligand signatures in primary cell cultures.
Discussion
In the present study, we demonstrate that impedance responses
provide an integrative assessment of the cellular consequence to
GPCR stimulation, representing a holistic readout of the various
signaling events elicited in real-time. In addition, clustering
analyses of the impedance responses provided a means to sub-
classify ligands in a manner that was predictive of their signaling
profiles and revealed a richer signaling texture among b-
adrenergic ligands than previously envisaged.
Analysis of the b2AR-promoted impedance response to ISO
stimulation revealed the contribution of both Gs and Gi coupling,
Gbc-dependent signaling, as well as cAMP production, ERK1/2
activation and a novel Ca
2+ mobilization response to the overall
changes in cellular impedance. The observation that elements of
the impedance response that were blocked upon Gs or Gi
inactivation following chronic treatment with CTX and PTX,
respectively, could not be fully recapitulated by acute pharmaco-
logical inhibition of cAMP or ERK1/2 pathways suggests the
contribution of additional G protein-dependent signaling. How-
ever, we cannot rule out the possibility that chronic inhibition of G
proteins leads to cellular changes (e.g. changes in expression of
signaling or adhesion proteins) that indirectly affect the impedance
response. Our analysis also provided evidence that both cAMP
and ERK1/2 pathways converge on a common downstream
effector that mediates their contribution to the impedance
response, although the identity of this target remains unknown.
The impedance responses generated following b2AR stimula-
tion was found to be extremely sensitive to inhibition of
intracellular Ca
2+ mobilization. Although the b2AR has previously
been shown to increase intracellular [Ca
2+] through modulation of
L-type voltage-gated Ca
2+ channels [29] and the ryanodine
receptor [30], our data implicate a novel IP3-gated release of
Ca
2+ from intracellular stores. Ca
2+ is a well-established regulator
of actin cytoskeleton dynamics [31,32] and plays an important role
in controlling cellular adhesion and morphology, through effectors
such as cadherins [33] and annexins [34], potentially providing a
key mechanistic link between b2AR stimulation and the
impedance changes observed. Although we found this de novo
Ca
2+ release to contribute to the rapid ascending phase of Groups
I and II ligands, the impedance responses of ligands that do not
themselves induce a Ca
2+ mobilization are also sensitive to a
disruption of intracellular Ca
2+ homeostasis, stressing the impor-
tance of Ca
2+ in the cellular mechanisms that initiate an
impedance response. We propose that the normal resting
Figure 8. b-adrenergic ligand impedance responses in rat aortic
vascular smooth muscle cells (VSMCs). (A) Pre-treatment with the
b2-selective antagonist ICI118,551 (100 nM) for 1 hour completely
abolishes the impedance response obtained following stimulation with
1 mM ISO in VSMCs. (B) Impedance signatures for b-adrenergic ligands
representing each of the 5 compound classes defined in 6HisHA-b2AR-
HEKS cells. (C) Complete linkage hierarchical clustering of ligand
impedance responses determined by comparing the area between
individual curves (see Materials and Methods). The dashed line
represents the calculated threshold value defining compound dissim-
ilarity. Data represent the means from at least three independent
experiments.
doi:10.1371/journal.pone.0029420.g008
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2+ is necessary and sufficient to
permit the cytoskeleton to respond to subsequent signaling events,
such as cAMP production or ERK1/2 activation, and that ligands
that induce an additional increase in intracellular [Ca
2+] further
sensitize the cell to these signaling inputs leading to an
enhancement of the impedance response. Thus, the overall
impedance signature of a given ligand truly represents the
integration of the signaling pathways activated.
The contribution of multiple signaling events to the overall
impedance response challenges some of the efforts that have been
made to reduce such integrated responses to the engagement of a
single G protein [17,18]. It is now widely accepted that many
GPCRs promiscuously couple to and activate signaling through
multiple G protein subtypes [3] as well as G protein-independent
pathways. In the current study, we observed that both Gs- and Gi-
dependent signaling were integrated in the overall b2AR-
promoted response. Moreover, the fact that the signatures
obtained in VSMCs were dramatically different from those
observed in 6HisHA-b2AR-HEK293S cells highlights the cell-
type dependency of the impedance response, which likely reflects
differences in the relative abundance of signaling molecules and/
or mediators underlying the changes in cell shape and adhesion
that give rise to the impedance responses. These observations
highlight the inherent complexity of signaling systems and their
measurement and demonstrate the diversity of cellular responses
that can be generated by the stimulation of a given GPCR in
different cell contexts. The ability to detect and dissect these
complex cellular responses, as demonstrated in the present study,
provides information concerning the full signaling repertoire of a
receptor that can be more useful in drug discovery than the
attempt to ascribe a single signaling pathway to a receptor.
The fact that multiple signaling events are integrated in the
impedance response makes it an appealing platform to classify
compounds based on their signaling repertoire. Clustering of the
impedance responses generated by a series of b-adrenergic ligands
revealed an unprecedented level of ligand texture at the b2AR,
demonstrating the existence of at least five groups of compounds
with distinct impedance signatures. Previous work assessing the
signaling profiles of b-adrenergic ligands towards cAMP and
ERK1/2 pathways alone using endpoint-specific assays proposed
the existence of 3 distinct compound classes [11]. The ability of
impedance measurements to detect additional ligand diversity
likely reflects the contribution of other pathways not previously
assessed. Furthermore, differences in ligand signaling profiles
between this study and the former demonstrate the critical
influence of assay conditions on the reported signaling properties
of a ligand. In the present study, cAMP accumulation and ERK1/
2 activation were measured in conditions identical to those used
for impedance measurements. Without serum starvation, ligands
such as propranolol and ICI did not generate a detectable ERK1/
2 response, as previously reported [11,12]. However, differences in
their respective impedance responses indicated distinctions in the
overall cellular response induced by ICI and propranolol, which
had not previously been observed.
Although cell-based, integrative assays have begun to be
employed in some screening applications [35–38], our results
represent a first proof-of-principle of how they can be used not
only to identify potential ligands for a given target, but also to
differentiate classes of compounds with specific signaling profiles
that may correlate with therapeutic or adverse effects. We also
demonstrate the unique ability of integrative assays such as
impedance measurements to illuminate novel biology not yet
revealed by traditional single endpoint assays. The approaches
described should be universally applicable to all label-free
platforms that provide an integrative cell response, including both
impedance-based systems and those based on dynamic mass
redistribution. Most certainly, analytical integrative methodologies
such as the one presented here, will provide a more in-depth
exploration of cellular signaling dynamics and should be
transformative in the future of drug discovery.
Materials and Methods
Materials and reagents
Gallein was obtained from Tocris, U0126 from Cayman, and
bucindolol was a generous gift from Dr. Michael Bristow
(University of Colorado Health Sciences Center, Denver, CO).
Cell culture reagents were from Wisent Incorporated. Other
reagents were obtained from Sigma-Aldrich unless stated other-
wise.
Stable cell lines and transfection
The pIREShygro_6HisHA-b2AR construct was generated as
follows: The 6HisHA-b2AR gene was amplified by PCR from the
previouslydescribedvectorpCDNA3RSV-6HisHA-b2AR[39]using
sense and antisense primers containing BsrGI and NheI restriction
sites, respectively. The amplified 6HisHA-b2AR sequence was
digested with BsrGI/NheI and then subcloned in a BsrGI/NheI-
digested pIREShygro3 vector (Clontech, Mountain View, CA).
The 6HisHA-b2AR-HEK392S polyclonal cell line was generated by
transfecting the pIREShygro_6HisHA-b2AR construct in
HEK293S cells [40] and selecting vector-inserted cells by growth
in culture media containing 100 mg/ml hygromycin B (WISENT
inc,St-Bruno,Quebec,CAN).The6HisHA-b2AR-HEK293Sstable
cell line was found to express 1.0760.14 pmol of 6HisHA-b2AR per
mg of membrane protein as determined by a
125I-CYP radioligand
binding assay. Cells were routinely grown at 37uCw i t h5 %C O 2 in
Dulbecco’s modified Eagle’s medium supplemented with 5% fetal
bovine serum.For Ca
2+ assays and impedanceassays inthe presence
of the MEK dominant negative mutant, 6HisHA-b2AR HEK293S
cellsweretransientlytransfectedwiththeobelinbiosensor[41]orthe
MEK1-K97A-Flag mutant [42], respectively, using polyethyleni-
mine and assayed 48 hours later.
Cellular impedance assay
The xCELLigence system (Roche Applied Science) was
employed to measure changes in cellular impedance following
ligand stimulation [43]. Briefly, this assay is based on the principle
that the adhesion of cultured cells directly onto an array of equally-
distributed microelectrodes embedded at the bottom of wells of a
microtitre plate induces changes in the local ionic environment at
the electrode/solution interface, conferring an increase in electrode
impedance. As a result, any changes in cell physiological properties
that modulate the physical contact between cell and electrode, such
as changes in morphology and/or adhesion, will be reflected by
changes in the measured impedance, as defined by the cell index
variable. A measurement is made inthepresence ofgrowth medium
prior to cell seeding to determine the background cell index in each
well of a 96-well E-plate (Roche Applied Science), which is
subtracted from the cell index values generated following cell
attachment. Cells were plated at a cell density of 20 000 cells/well
and grown for 16–20 hours before ligand addition in the RTCA SP
device station (Roche Applied Science). When cells were treated
with cholera toxin or pertussis toxin, they were plated at a cell
density of 10 000 cells/well, treated with toxins after 24 hours and
stimulated with ligand 40 hours after seeding. Experimental
variation in cell index values at the time of treatment was limited
to 620%, which considerably increased the reproducibility of the
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cell index values were obtained immediately following ligand
stimulation every 20 seconds for a total timeof at least 100 minutes.
Cell index values were normalized by dividing by the cell index at
thetimeofligand additionandbaseline-correctedbysubtractingthe
cellindexobtainedinvehicle-treatedconditions(seeFigureS9).All
data presented in figures represent means of at least three
independent experiments.
cAMP accumulation assay
Cells were plated, grown in 96-well plates and treated with
ligand as described for the cellular impedance assay. cAMP
accumulation was measured using the HTFR-cAMP dynamic kit
(Cisbio). After 10 minutes of ligand stimulation, cells were lysed on
ice in the lysis buffer provided by the manufacturer and
immediately snap-froze at 280uC for at least 4 hours. After
thawing on ice, 10 ml per well of lysate was transferred to a 384-
well plate (Lumitrac 200, Greiner Bio-one), and cAMP measure-
ments were performed as per manufacturer’s instructions.
ERK1/2 activation assay
Cells were plated, grown in 96-well plates and treated with
ligand as described for the cellular impedance assay. ERK1/2
activation was measured using the ERK1/2 AlphaScreen Surefire
kit (Perkin Elmer). Cells were lysed on ice after 2 minutes of ligand
stimulation in the lysis buffer provided by the manufacturer and
placed immediately at 220uC overnight. After thawing on ice, 5 ml
weretransferred to 384-well ProxiPlates (Perkin Elmer) and ERK1/
2 activation was measured as per manufacturer’s instructions.
Obelin Ca
2+ biosensor assay
Cells were plated, grown in 96-well microtitre plates and
transfected as described above. Forty-eight hours after transfec-
tion, growth medium was replaced with Tyrode’s solution (1 mM
CaCl2, 140 mM NaCl, 2.7 mM KCl, 900 mM MgCl2,3 7mM
NaH2PO4, 5.6 mM d-glucose, 8.3 mM NaHCO3 and 12.6 mM
Hepes, pH 7.5) and cells were incubated with 5 mM coelanter-
azine H (Nanolight Technology, Pinetop, AZ, USA) for 2 hours.
Intracellular Ca
2+ concentration is reflected by the magnitude of
bioluminescence emitted by the obelin biosensor and data are
expressed as relative luminescence units (RLU). Ligands were
injected as indicated and bioluminescence was measured for
1 minute per condition using the SpectraMax L Microplate reader
(Molecular Devices). Baseline readings were obtained for 5 sec-
onds prior to ligand addition and subtracted from post-injection
readings to obtain a ligand-induced Ca
2+ response. Peak Ca
2+
responses represent the maximum response in the largest peak
obtained following ligand addition. Peaks were defined to have a
minimum width of ten adjacent points.
Data analysis
Data analysis was performed using Microsoft Excel (Microsoft,
Redmond, WA, USA), GraphPad Prism 5 (GraphPad Software, La
Jolla, CA, USA) or MATLAB (The MathWorks, Natick, MA, USA).
To quantify the slope of the rapid ascending phase, a line was drawn
from two data points after the minimum (to avoid artifacts from
shallowminima)tomaximumresponse,andtheimpedanceresponse
was bisected at the point farthest from that line. Then, a second line
was drawn from two data points after minimum response to the first
bisection point, and the impedance response was bisected again.
Slope was calculated as the ratio between the difference in
impedance and the difference in time between two data points after
the minimum response and the second bisection point.
Differences in ligand impedance signatures were determined by
calculating the area between their impedance curves. The area A
between two curves i and j was estimated as
Ai,j~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ X
t
(Ii,t{Ij,t)
2
r
where Ii,t is the impedance response of curve i at time t.
Clustering of the data was assessed using the visual assessment of
tendency method (VAT) [44]. Briefly, arrays of the pairwise
dissimilarities were sorted by placing the two ligands with the
highest pairwise dissimilarity in the first and last rows, respectively.
The array was then populated with the remaining ligands by
minimizing the dissimilarity among adjacent compounds and
maintaining the same order of compounds in rows and columns.
To emphasize cluster structure among similar data points, the
square root of the sorted dissimilarity maps were displayed.
For complete linkage hierarchical clustering, clustering trees
were cut at 0.8 times the median of all pairwise dissimilarities.
Supporting Information
Figure S1 ISO-promoted impedance response is b2AR-
specific. (A) Impedance response upon ISO stimulation following
1 hour pre-treatment with the b2AR-selective antagonist
ICI118,551 (ICI) or the b1AR-selective antagonist CGP20712A
(10 mM each). (B) Concentration-response curves of ISO-promot-
ed maximum impedance response following pre-treatment with
increasing concentrations of ICI118,551. Data represent the
means from three independent experiments (+/2 SEM for B).
(TIF)
Figure S2 Signaling and impedance responses in pa-
rental HEK293S and 6HisHA-b2AR-HEK293S cells. (A)
Comparison of the impedance responses observed in parental
HEK293S and 6HisHA-b2AR-HEK293S stable cell lines following
treatment with ISO (1 mM). (B) Impedance responses upon ISO
stimulation in the presence or absence of a 1 hour pre-treatment
with the b2AR-selective antagonist ICI118,551 (ICI, 10 mM) in the
parental HEK293S cells, demonstrating that the response observed
in these cells resulted from activation of endogenous b2AR. (C,D)
The ISO-promoted cAMP production (C) and ERK1/2 activation
(D) observed in the parental HEK293S expressing low levels of
endogenous b2AR was potentiated by the overexpression of human
b2AR in 6HisHA-b2AR-HEK293S cells. Accumulation of cAMP
was detected using the EPAC cAMP biosensor (M. Leduc, B.
Breton and N. Heveker, et al. J. Pharmacol. Exp. Ther., 331 (2009),
pp. 297–307). Data represent means of at least three independent
experiments. Statistical significance of the differences between the
conditions for panels C and D were assessed using Student’s paired
t-test. ** P,0.01, * P,0.05.
(TIF)
Figure S3 Involvement of the MEK/ERK1/2 pathway in
the ISO-promoted impedance response. Cells were trans-
fected or not (Mock) with the MEK1-K97A-Flag dominant
negative mutant 48 hours prior the impedance measurements
and treated with ISO (1 mM). Data represent means of three
independent experiments.
(TIF)
Figure S4 Comparison of the direct inhibition of Gas,
Gbi and Gbc vs inhibition of cAMP and ERK1/2
pathways on the impedance response. (A) Comparison of
cholera toxin (CTX) and SQ22536 pre-treatments on the ISO-
promoted impedance response (Figure 2A and 3A). (B) Compar-
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ISO-promoted impedance response (Figure 2B and 3A). (C)
Comparison of gallein (Gall) and U0126 pre-treatments on the
ISO-promoted impedance response (Figure 2B and 3D).
(TIF)
Figure S5 Statistical analysis of the variability of
impedance responses. (A–E) Repeated impedance responses
were obtained for ligands from each of the five groups of
compounds. In each case, 3–7 independent measurements were
made and mean impedance values (CI) were determined for each
time-point. The mean impedance responses are shown in solid,
colored lines whereas the dotted black lines represent the standard
error of the mean (SEM) for each time-point.
(TIF)
Figure S6 Visual assessment of clustering tendency of
-adrenergic ligand impedance signatures. Gray levels
represent the extent of dissimilarity between ligands as determined
by area between the curves, ranging from black (smallest
difference) to white (largest difference). Ligands are ordered based
on similarities in the area between their curves. Ligands with
similar impedance signatures (small differences in area between
the curves) are visualized as dark clusters along the diagonal. See
Materials and Methods for additional information.
(TIF)
Figure S7 ISO-induced Ca
2+ response is b2AR-specific.
6HisHA-b2AR-HEK293S were pre-treated or not with the b2AR-
selective antagonist ICI118,551 (100 nM) for 1 hour before
stimulation with 1 mM ISO. Data represent means of three
independent experiments (6 SEM).
(TIF)
Figure S8 Effect of thapsigargin on ISO-induced Ca
2+
and impedance responses. ISO-induced Ca
2+ response (A)
and impedance response (B) upon pre-treatment or not with
thapsigargin (TG, 5 mM) for 30 minutes. Data represent means
(+/2 SEM for A) from at least three independent experiments.
(TIF)
Figure S9 Normalization and baseline-correction of
impedance responses. (1) A measurement of cell index is
made in the presence of growth medium prior to cell seeding to
determine the background cell index in each well, which is
subtracted from the cell index values generated by cell attachment.
Cells are grown for 16–20 hours before ligand treatment. (2) Cell
index values are obtained immediately following ligand treatment
every 20 seconds for a total time of at least 100 minutes. (3) Cell
index values are normalized by dividing by the cell index at the
time of ligand addition and (4) baseline-corrected by subtracting
the cell index obtained in vehicle-treated conditions. See Materials
and Methods for more details.
(TIF)
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